Traders should monitor the full data presentation at DDW on May 2 for insights into efficacy and safety, which could catalyze near-term upside. Positive results may attract institutional interest or collaboration offers, particularly given the unmet need in pancreatic cancer.
Price Chart
Executive Summary
Alpha Tau Medical announced that clinical data from its Alpha DaRT therapy for pancreatic cancer has been accepted for an oral presentation at Digestive Disease Week (DDW) 2026, marking the first time this data will be presented at a major gastroenterology conference. This represents a significant milestone in validating the scientific and clinical potential of its technology for a high-need indication.
Key Facts
- Alpha DaRT pancreatic cancer clinical data accepted for oral presentation at DDW 2026, the premier gastroenterology conference.
- Presentation based on combined results from two first-in-human trials at Hadassah Medical Center in Jerusalem.
- Data to be presented on May 2, 2026, by Dr. Harold Jacob, Principal Investigator.
- Company highlights this as a key milestone supporting ongoing clinical development, including the U.S.-based IMPACT pilot study.
- Pancreatic cancer is a high-mortality disease with limited treatment options, especially for inoperable cases.
Financial Impact
No direct financial impact disclosed; potential for increased investor and clinical interest leading to future funding or partnership opportunities.
Risk Factors
- Data presented may be preliminary or limited in sample size.
- Forward-looking statements emphasize risks including regulatory approval, funding needs, and clinical trial enrollment.
- No guarantee that presentation will lead to commercial or regulatory advancement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-036954 |
| Document: ea028432201ex99-1.htm | 0001213900-26-036954 |
| Document: 0001213900-26-036954-index-headers.html | 0001213900-26-036954 |
| Document: 0001213900-26-036954-index.html | 0001213900-26-036954 |
| Document: 0001213900-26-036954.txt | 0001213900-26-036954 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 17w ago | 6-K | $1.02 $4.00 | ▲ +292.16% | ▲ +289.66% | — |
Jun 1, 2026 17w ago | 6-K | $1.02 $3.89 | ▲ +281.37% | ▲ +280.14% | — |
May 18, 2026 19w ago | 6-K | $1.02 $3.89 | ▲ +281.37% | ▲ +275.08% | — |
May 11, 2026 20w ago | 6-K | $1.02 $3.37 | ▲ +230.39% | ▲ +226.00% | — |
May 11, 2026 20w ago | 6-K | $1.02 $3.37 | ▲ +230.39% | ▲ +226.00% | — |
May 8, 2026 21w ago | 6-K | $1.02 $3.30 | ▲ +223.53% | ▲ +218.69% | — |
May 8, 2026 21w ago | 6-K | $1.02 $3.30 | ▲ +223.53% | ▲ +218.69% | — |
May 7, 2026 21w ago | 6-K | $1.02 $2.58 | ▲ +152.94% | ▲ +149.11% | — |
May 5, 2026 21w ago | 6-K | $1.02 $2.70 | ▲ +164.71% | ▲ +161.97% | — |
May 4, 2026 21w ago | 6-K | $1.02 $2.29 | ▲ +124.51% | ▲ +122.65% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access